Tellus BioVentures is a biotechnology investment fund focused on early-stage innovation and company formation.

About Us

Tellus BioVentures is a biotechnology investment fund focused on early-stage innovation and company formation.

About Us

Featured News

Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease

08/15/22  Viridian Therapeutics, Inc. (NASDAQ: VRDN) today announced positive initial clinical data from the 10mg/kg cohort in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED).

Continue reading

Penn Spinout Vittoria Biotherapeutics Emerges from Stealth Mode with $10M Seed Round

06/07/22  A Philadelphia life sciences company spun out of a University of Pennsylvania research lab is emerging from stealth mode with nearly $10 million from a seed funding round.

Continue reading

Dianthus Therapeutics Launches with $100M to Develop Selective Antibody Complement Therapeutics to Treat Severe and Rare Autoimmune Diseases

05/03/22  Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced the completion of its $100 million Series A financing led by 5AM Ventures, Avidity Partners, and Fidelity Management & Research Company, with participation from additional investors including Wedbush Healthcare Partners and founding investors Fairmount, Tellus BioVentures, and Venrock Healthcare Capital Partners.

Continue reading

Mission

  • To uncover and accelerate promising life science innovation
  • To enable talented entrepreneurs and innovators
  • To serve patients with unmet needs
Learn More

Investments

We make select early investments at the Seed stage in private biotech ventures as the lead or sole investor and participate in Series-A investments.

Company Formation

We launch and fund de novo companies to advance important innovations that may otherwise lack the proper resources to progress efficiently.

Approach & portfolio